Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma.

The Journal of clinical investigation - 15 Nov 2021

Clark-Garvey Sean, Kim William Y

Abstract excerpt

Despite recent therapeutic gains in the treatment of advanced bladder cancer, the overall survival in patients with metastatic disease remains poor and further therapeutic discovery is needed. Advanced bladder cancer is a molecularly heterogeneous disease, and the identification of driver genetic alterations has led to effective targeted therapeutic agents, such as fibroblast growth factor receptor (FGFR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Transitional Cell
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptors, Fibroblast Growth Factor

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34779406
DOI: 10.1172/JCI154095
PMCID: PMC8592532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma.PMID 34779406Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cellsSemantic proximity Read ↗

Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the BladderSemantic proximity Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progressionSemantic proximity Read ↗

Characterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

Raf-interactome in tuning the complexity and diversity of Raf function.Semantic proximity Read ↗

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitorsSemantic proximity Read ↗

Molecular Landscape of Non-Muscle Invasive Bladder Cancer.Semantic proximity Read ↗

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.